{"name":"Zhejiang Doer Biologics Co., Ltd.","slug":"zhejiang-doer-biologics-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"DR10624 Injection","genericName":"DR10624 Injection","slug":"dr10624-injection","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"DR10624 Injection","genericName":"DR10624 Injection","slug":"dr10624-injection","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxPWEZGT1RkQkRSUVRxWXZSSXoyMmt5TnJaWG5MWVo5UzU1MnhhenM1RWNoNlFVUHZqS0Q3c0VTU3E4UmFkSXlPU2liZXZpR19BbTB3MTBXVlhvUS1YZ3dacmFjVUpLRVhoSGRBYTE2YUdySHVxWDk4bzFZRkhjRXpSZFQzem8ySmd6LXd3MGtOM2habEtBZUFUMWMwMEdHa0cwaXItdlpxZlZzTUFPQUlLekRCOUNIYldRY0h6TmJCbjBpY2xpdUIwNGxCY09mRFFYYUxtZDcta3hta09kRDdsQ25fVjRncExpRFU1eVRXeFRMQkl0cG15Q0Z3dzN6cUU?oc=5","date":"2026-04-02","type":"trial","source":"Barchart.com","summary":"Severe Hypertriglyceridemia Clinical Trial Pipeline Expands as 8+ Companies Driving Innovation in the Therapeutics | DelveInsight - Barchart.com","headline":"Severe Hypertriglyceridemia Clinical Trial Pipeline Expands as 8+ Companies Driving Innovation in the Therapeutics | Del","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-04-23","type":"trial","source":"PR Newswire","summary":"Doer Biologics Announces First Patient Dosed in Phase 2 Study of DR10624 for Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis ","headline":"Doer Biologics Announces First Patient Dosed in Phase 2 Study of DR10624 for Treatment of Metabolic Dysfunction-Associat","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxQQlJrc2NYdWtIWkU3MlJIZk4zZnRnVU0xaGpSSDl5OW5HLTdWZ18zZjdLZFFmaUVjZ19TbThRcWVPYk9DWjA0dmNGSnFqT3h0ZlVyRnRDM1pTNzNXUUJ0SGNOemNqR3EzSUhsYUZNVXFOd3AzcXNNcDFRcDJpX2ZoajI3cDgyQktaY3ZiQjlXb0RyWVJDc2VIYmxXVVNxR19aVXFlLVFUYXFfYXVaa2tmd0h5SWZJVE92QXZsMURvRS1hUmpkWGlCRGd3SDlRYldfTHFFNTBjX2EtWTZOaU5HVUJBUTdXQmFw?oc=5","date":"2024-10-01","type":"trial","source":"BioPharma APAC","summary":"Doer Biologics Begins Phase 2 Study of First-in-Class Tri-Agonist DR10624 for Severe Hypertriglyceridemia - BioPharma APAC","headline":"Doer Biologics Begins Phase 2 Study of First-in-Class Tri-Agonist DR10624 for Severe Hypertriglyceridemia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxQbmNFYV9EaG1qWTA5Zi1XQlpNeVdxbklKSEdveDJtQXJkdUhXWERUMVlFelZubEFqV2hKR2l0aVYtZTJBY1VUWnY0bGVGYlpDcXlCeVVpSDFDREZFdE5pOWRab3h1T2NMVUV3WXdUY3A0YWZxUjZ5N3dsQTJJUHk4TGVVSE9VRGR3QzRvSWFMZ3paZjR0Z2pGeHZTeFZ4eS0wdWVBLTZSUXNNTHpNTHo2amhlNFEyalJqb3ZzRzJyNmRKd2Vla1RMWlZzY0RhLXJjNVVOaHdyeUVFcDZZZEdWVXR1MWRRbGhFYnZDUkdn?oc=5","date":"2024-09-30","type":"trial","source":"BioSpace","summary":"Doer Biologics Announces First Patient Dosed in Phase 2 Study of DR10624 for Treatment of Severe Hypertriglyceridemia - BioSpace","headline":"Doer Biologics Announces First Patient Dosed in Phase 2 Study of DR10624 for Treatment of Severe Hypertriglyceridemia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxOZzNBQlFvNUVwa2RpY0RCMm40Yno0QmJvWUMtdzJwM2d6YXdxU3psaEFPeFc1eUpWNjJ3cWhtZ1gtVU1GbmY4THVQRjJZMk9ldlVaN0hhUEVlMS1rWjZmRkw2RWRXc2RVNEUxdGlKVm5VamFuWWs4c1hLMGo1eDNMQktiVzRYZEx0bFVBVEIwd2R4eUk5dUItMXB2RTk4cmZhSUxVZ2R4NF9TS3ZSSC1Fcl9aU0pxdnhHQzFkNjM3eHIwT2xtUm1LSlgyTzFUcUFkbEFKZTh0ZEoxSWlmS01ubXZ6LWpVWjlBTFgycmpZazdMUnhaendIWVFhVEFON25yMTdVV2djc0xTc0NiZUZrNXpaVFcxb1FFelJseWdTWQ?oc=5","date":"2024-07-05","type":"trial","source":"PR Newswire","summary":"Zhejiang Doer Biologics Completes Enrollment of the Phase 1b/2a Trial Evaluating DR10624 in Obese Subjects with Modest Hypertriglyceridemia - PR Newswire","headline":"Zhejiang Doer Biologics Completes Enrollment of the Phase 1b/2a Trial Evaluating DR10624 in Obese Subjects with Modest H","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE1pVXBpbnNHNmxBMVBVZjBlT0czcXFqVEVxVkZOVWVYSERvQ0xwQ21vT19CTWRVNm9RVFdiMVNTX2tQbkVuQVR0X1d3TUpVUHJYLU5hZG1lZ3NjelhzZzJLVDhSMTdaaktDa3VHMW8yYjZvekE?oc=5","date":"2023-11-27","type":"trial","source":"Oncology Pipeline","summary":"TROP2 gets more crowded | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"TROP2 gets more crowded | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxQa2NBSF9nTVF1cTd4aXNPZHdyWHlOcG9wUEQxYWlQUEVsRVR4U3FyRld0V29rTXp1WVllZi1XRmJJY3BJQ2NZaFFqblZqZUd5NmlBVktVdUVtbVFmYnF3Q2ZrUXR1TE95QXY4N0o5V05lYmxOajhUc01Dc3V1cGhBVmQ0dUNWNk9lT29DbzJBbTY4SWNIOTFWaDhhMEE5T1J0OXlvRGNKWEd3ZUREdWQ1OHFmSmpvS3RPRi0zSTcxR0RGZw?oc=5","date":"2023-10-29","type":"regulatory","source":"BioPharma APAC","summary":"Doer Biologics Initiates Phase I MAD Trial of DR10624, Receives NMPA IND Approval - BioPharma APAC","headline":"Doer Biologics Initiates Phase I MAD Trial of DR10624, Receives NMPA IND Approval","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNMC1kX1VYYWxON2poWG1NdGZVTW5DUWVVbG10dXdaYjZ6NUQ1WE1qV3d4bjBWelpLb1dhRHZfN1hDWUhyY00xT0FvRi1Qd1A5ZVMwNnN1bUVyWktfNGh1RUdZOW9PMENDeWNpVDh4T3pqeWZpRXl4bkkta2twMk15OFM4LTNFZFdUX1ZObGlPSl9PR293bmxydE9fSEstcFZDRkJGOVFHV3dlVGZNd19yUnZB?oc=5","date":"2023-07-10","type":"deal","source":"PR Newswire","summary":"Doer Biologics Announces License Agreement with BioNTech - PR Newswire","headline":"Doer Biologics Announces License Agreement with BioNTech","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}